Blood biomarkers to predict the efficacy of neoadjuvant chemo-immunotherapy in non-small cell lung cancer patients
In patients receiving neoadjuvant chemo-immunotherapy, high pre-treatment SCCA levels and low post-treatment PLRs were significantly associated with better efficacy and survival. Thus, these biomarkers could be used to guide the choice of treatment modalities.
Authors
- Kentaro Inamura (ORCID: https://orcid.org/0000-0001-6444-3861)
- Yang Pan (ORCID: https://orcid.org/0000-0003-3962-4278)
- Jingwei Lin (ORCID: https://orcid.org/0000-0001-8725-0528)
- Yan Zhang (ORCID: https://orcid.org/0000-0002-5027-6430)
- Xuanhong Jin (ORCID: https://orcid.org/0009-0002-9348-1837)
- Yuxia Wang (ORCID: https://orcid.org/0009-0007-2444-4000)
- Feng Li (ORCID: https://orcid.org/0000-0002-0763-014X)
- Jian Zeng (ORCID: https://orcid.org/0000-0002-4565-920X)
- J. J. Hong (ORCID: https://orcid.org/0000-0002-1685-8090)
- Haoting Xu (ORCID: https://orcid.org/0009-0005-1036-6633)
- Jinhao Zhang (ORCID: https://orcid.org/0009-0001-3898-4901)
- Kailai Yin
- Dujiang Liu
Institutions
- Jichi Medical University (JP)
- Shaoxing University (CN)
- Chinese Academy of Sciences (CN)
- Fudan University (CN)
- Wenzhou Medical University (CN)
- Sir Run Run Shaw Hospital (CN)
- Zhejiang Cancer Hospital (CN)
- Huashan Hospital (CN)
- Japanese Foundation For Cancer Research (JP)
- Zhejiang University (CN)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2024-10-01
- DOI
- https://doi.org/10.21037/tlcr-24-717
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.85